EUVIMEDEUVIMED entdecken
Crossref

Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis

Magnus Bock iD, Johan G C Van Hasselt iD, Franziska Schwartz iD, Hengzhuang Wang, Niels Høiby, Kurt Fuursted, Nikolaj Ihlemann, Sabine Gill iD, Ulrik Christiansen, Niels Eske Bruun, Hanne Elming, Jonas A Povlsen und 12 weitere

Journal of Antimicrobial Chemotherapy · 01.12.2023 · 78 (12) · 2840-2848

DOI: 10.1093/jac/dkad316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 12.10.2023. Verfasst von Magnus Bock und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Rifampin, Endocarditis, Bacterial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Danish Heart Foundation, Capital Regions Research Council, Hartmann's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Linezolid in combination with rifampicin has been used in treatment of infective endocarditis especially for patients infected with staphylococci.

Objectives

Because rifampicin has been reported to reduce the plasma concentration of linezolid, the present study aimed to characterize the population pharmacokinetics of linezolid for the purpose of quantifying an effect of rifampicin cotreatment. In addition, the possibility of compensation by dosage adjustments was evaluated. Patients and methods Pharmacokinetic measurements were performed in 62 patients treated with linezolid for left-sided infective endocarditis in the Partial Oral Endocarditis Treatment (POET) trial. Fifteen patients were cotreated with rifampicin. A total of 437 linezolid plasma concentrations were obtained. The pharmacokinetic data were adequately described by a one-compartment model with first-order absorption and first-order elimination.

Results

We demonstrated a substantial increase of linezolid clearance by 150% (95% CI: 78%–251%), when combined with rifampicin. The final model was evaluated by goodness-of-fit plots showing an acceptable fit, and a visual predictive check validated the model. Model-based dosing simulations showed that rifampicin cotreatment decreased the PTA of linezolid from 94.3% to 34.9% and from 52.7% to 3.5% for MICs of 2 mg/L and 4 mg/L, respectively.

Conclusions

A substantial interaction between linezolid and rifampicin was detected in patients with infective endocarditis, and the interaction was stronger than previously reported. Model-based simulations showed that increasing the linezolid dose might compensate without increasing the risk of adverse effects to the same degree.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinEndocarditis, BacterialHumansLinezolidAnti-Bacterial AgentsMitomycin

Substanzen

LinezolidRifampinAnti-Bacterial AgentsMitomycin

Autor:innen und Institutionen

  • Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  • Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
  • Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark.
  • Department of Cardiology, Odense University Hospital, Odense, Denmark.

ORCID-Profile: Magnus Bock, Johan G C Van Hasselt, Franziska Schwartz, Sabine Gill, Lars Køber, Flemming S Rosenvinge, Christian Torp-Pedersen, Kasper Iversen, Henning Bundgaard

Förderung

  • Danish Heart Foundation
  • Capital Regions Research Council
  • Hartmann's Foundation
  • Svend Aage Andersens Foundation
  • Novo Nordisk Foundation
  • Borregaard Clinical Scientist Fellowship
  • Hartmann’s Foundation

Zitieren

APA

Bock, M., Van Hasselt, J. G. C., Schwartz, F., Wang, H., Høiby, N., Fuursted, K., Ihlemann, N., Gill, S., Christiansen, U., Bruun, N. E., Elming, H., Povlsen, J. A., Køber, L., Høfsten, D. E., Fosbøl, E. L., Pries-Heje, M. M., Christensen, J. J., Rosenvinge, F. S., Torp-Pedersen, C., …, & Moser, C. (2023). Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis. Journal of Antimicrobial Chemotherapy, 78(12), 2840-2848. https://doi.org/10.1093/jac/dkad316

Vancouver

Bock M, Van Hasselt JGC, Schwartz F, Wang H, Høiby N, Fuursted K, et al. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis. Journal of Antimicrobial Chemotherapy. 2023;78(12):2840-2848. doi:10.1093/jac/dkad316

BibTeX
@article{Bock2023,
  author = {Bock, Magnus and Van Hasselt, Johan G C and Schwartz, Franziska and Wang, Hengzhuang and Høiby, Niels and Fuursted, Kurt and Ihlemann, Nikolaj and Gill, Sabine and Christiansen, Ulrik and Bruun, Niels Eske and Elming, Hanne and Povlsen, Jonas A and Køber, Lars and Høfsten, Dan E and Fosbøl, Emil L and Pries-Heje, Mia M and Christensen, Jens Jørgen and Rosenvinge, Flemming S and Torp-Pedersen, Christian and Helweg-Larsen, Jannik and Tønder, Niels and Iversen, Kasper and Bundgaard, Henning and Moser, Claus},
  title = {Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {12},
  pages = {2840--2848},
  doi = {10.1093/jac/dkad316}
}
Kostenlos starten →